Uniflash® is a single-dose oromucosal solution for oral administration. The efficacy and speed of action of this new non-invasive transmucosal route of administration are comparable to that of an intravenous injection.
Thanks to this patented technology, lipophilic or amphiphilic molecules are rapidly absorbed through the oral mucosa. This highly vascularised mucosa allows the drug to pass rapidly into the bloodstream, thus considerably reducing the famous "hepatic first pass effect". This hepatic passage reduces the efficacy of the drug through metabolisation. Thus, by avoiding this passage effect, the quantity of active ingredient to be delivered at each intake is reduced, thus limiting the potential adverse effects of the drug.
*The first hepatic pass is the transformation of the drug during its first passage through the liver, before it reaches the systemic circulation, during oral administration.
Our sites are regularly inspected by various authorities including: ANSM (France), EU GMP (Europe), SKFDA (South Korea) and most authorities worldwide.
Colomiers, France
Bordeaux, France
